Targeting of human interferon antagonists
AssigneesVib Vzw, Universiteit Gent, Centre National De La Recherche Scientifique, Universite De Montpellier, Centre Hospitalier Regional Universitaire De Montpellier
InventorsJan Tavernier, Lennart Zabeau, Gilles Uze, Franciane Paul, Yann Bordat, Genevieve Garcin
Life of this patent
Estimating the term…
Abstract
The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
Claims5
A method for treating an autoimmune disease comprising providing to a subject in need thereof an effective amount of a composition comprising a fusion protein, the fusion protein comprising an interferon antagonist and a variable domain of camelid heavy chain antibody (VHH) or a variable domain of new antigen receptor (VNAR), wherein the interferon antagonist is a human interferon alpha 2 (IFNα2) comprising an R120E mutation and wherein the VHH or VNAR is directed to CD20.
Dependencies are inferred from the claim text.